KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.

Status

Suspended

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510082-10-00

Acronym

CJDQ443B12301

Enrollment

Registered

2024-09-10

Start date

2022-09-05

Completion date

Unknown

Last updated

2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer harboring the KRAS G12C mutation

Brief summary

Progression free survival (PFS) per RECIST 1.1 as assessed by the investigator

Detailed description

Type, frequency and severity of adverse events, changes in laboratory values, vital signs, ECGs

Interventions

DRUGDOCETAXEL

DRUGJDQ443

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS) per RECIST 1.1 as assessed by the investigator	—

Secondary

Measure	Time frame
Type, frequency and severity of adverse events, changes in laboratory values, vital signs, ECGs	—

Countries

Finland, Greece, Hungary, Iceland, Italy, Portugal, Romania, Slovenia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026